allogeneic hematopoietic stem cell transplantation (Northwestern University)

Allogeneic hematopoietic stem cell transplantation (HSCT) is an experimental cell-based biologic therapy developed by Northwestern University, specifically led by Dr. Richard Burt, for the treatment of severe, refractory rheumatoid arthritis. The approach involves a nonmyeloablative conditioning regimen consisting of fludarabine, cyclophosphamide, and alemtuzumab (CAMPATH-1H) to prepare the patient by depleting autoreactive immune cells. This is followed by the transplantation of CD34-selected allogeneic hematopoietic stem cells derived from an HLA-matched donor. The therapy aims to induce mixed chimerism—a state where both donor and recipient immune cells coexist—to reset the patient's immune system and eliminate the pathogenic immune response responsible for rheumatoid arthritis, potentially inducing long-term remission without the need for chronic immunosuppression.

Other names

allogeneic HSCTCD34-selected allogeneic hematopoietic stem cellsCD-34-selected allogeneic hematopoietic stem cellsCD 34-selected allogeneic hematopoietic stem cellsTolerance Induction by Mixed Chimerism